FormFactor director Sheri Rhodes sells $793,531 in shares

FormFactor reported Q1 2026 EPS of $0.56 versus $0.44 expected and revenue of $226.1 million versus $203.84 million consensus, while gross margin improved 510 bps sequentially to 49.0%. Analysts responded by raising targets, including Craig-Hallum to $175, Northland to $118, and Stifel to $135. Separately, director Sheri Rhodes sold 6,328 shares at $125.40 for about $793,531, leaving her with 5,375 shares.

Analysis

FORM’s setup looks increasingly like a classic late-cycle semiconductor equipment rerating: the market is rewarding margin inflection and guidance momentum faster than it is discounting eventual normalization. The key second-order effect is that stronger probe/test demand typically signals that leading-edge and advanced packaging customers are still in build mode, which is constructive not just for FORM but also for select inspection/test peers and outsourced manufacturing capacity that sits further down the chain.

The insider sale matters less as a bearish signal on fundamentals than as a sentiment marker after a very sharp run; when a name has already repriced nearly 3x, incremental upside usually depends on another leg of estimate revisions rather than simply “good results.” That makes the next 1-2 quarters crucial: if gross margin holds near this level and revenue re-accelerates, the stock can remain momentum-owned; if orders merely confirm rather than surprise, the valuation can compress quickly because equipment stocks tend to trade on forward EPS multiple durability rather than trailing beats.

The contrarian read is that the market may be extrapolating too much from one clean quarter. A 49% gross margin print is powerful, but in semi-capex businesses the more durable signal is book-to-bill and customer concentration, both of which can reverse faster than Street models reflect if a small number of AI/logic accounts pause spending. In that scenario, the sharpest risk is not a gentle de-rating but a fast unwind of crowded quality/momentum positioning over 4-8 weeks.

AVGO is more of a barometer here than a direct beneficiary: if broad semis roll over while FORM is still priced for perfection, the pair can diverge, but a continued AI infrastructure bid would keep the whole complex supported. The best trade is to express the view with controlled downside rather than outright stock exposure, because the upside case is already partly in the price while the downside is a multiple reset, not just earnings drift.

Key Decisions for Investors

• Short FORM on strength / buy-to-cover into any post-earnings continuation move over the next 2-4 weeks; risk/reward favors fading further multiple expansion after a 293% one-year run and an insider sale near current levels.
• Structure a FORM bearish put spread 1-3 months out to capture valuation compression if guidance stops improving; target a 1.5-2.5x payoff if the stock gives back even a modest portion of the recent rerating.
• Pair trade: long AVGO vs short FORM over the next 1-2 quarters; AVGO offers broader AI/infra exposure and lower single-name execution risk, while FORM is more vulnerable to a post-beat normalization in equipment multiples.
• If staying bullish, wait for a pullback rather than chasing the current level; re-enter only if the stock can hold after the next estimate revision cycle, otherwise upside is likely capped and downside convex.
• Watch next quarter’s margin and orders commentary as the real catalyst; if gross margin slips meaningfully or management sounds less confident on demand, reduce or exit quickly because the de-rating could happen over days, not months.